SBIR/STTR Research Award

SPECIFIC IMMUNOASSAY FOR THE BETA-2 ADRENERGIC RECEPTOR

Award identifier 2253f989abb939c12615e70fe4b9e4d4114254a0bfe6c466940bb65c0d178af3Awarding agency Department of Health and Human Services

Award amount

$257,213

Program and phase

SBIR · Phase II

Award year

1993

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Specialty Laboratories, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

THE BETA-2 ADRENERGIC RECEPTOR IS AN IMPORTANT NEUROTRANSMITTER RECEPTOR, WHICH IS INVOLVED IN THE REGULATION OF MULTIPLE CELLULAR SYSTEMS. DYSFUNCTION OF THERECEPTOR IS INVOLVED IN SEVERAL PATHOLOGICAL STATES INCLUDING ASTHMA, HYPERTENSION, MYOCARDITIS AND DILATED CARDIOMYOPATHY. MEASUREMENT OF BETA RECEPOR ACTIVITY RESTS PREDOMINANTLY ON THE BINDING ASSAY, WHICH HAS SEVERAL LIMITATIONS AND IS OF LIMITED CLINICAL UTILITY. THE GOAL IS TO PRODUCE SPECIFIC ANTIBODIES TO THE BETA ADRENERGIC RECEPTORS AND TO DEVELOP IMMUNOASSAYS USING THESE ANTIBODIES. TWO COMPLEMENTARY APPROACHES USING PROTEIN CHEMISTRY AND MOLECULAR BIOLOGY ARE DESCRIBED. IN THE FIRST APPROACH, ANTIGENIC REGIONS OF THE BETA ADRENERGIC RECEPTOR WILL BE IDENTIFIED USING THEORETICAL MODELS, PEPTIDES CORRESPONDING TO THESE SEQUENCES WILL BE SYNTHESIZED, ANTIBODIES PRODUCED IN RABBITS, AND THE ANTIBODIES EVALUATED FOR THE DETECTION OF THE DENATURED AND INTACT FORMS OF THE RECEPTOR. THE SECOND APPROACH INVOLVES EXPRESSING THE RECEPTOR IN E. COLI (AS A SECRETORY PROTEIN AND AS A BETA GALACTOSIDASE FUSION PROTEIN), IN A FORM WHICH RETAINS BINDING ACTIVITY AND PHARMACOLOGIC SPECIFICITY. THE EXPRESSED RECEPTOR WILL BE UTILIZED TO TEST THE ANTIBODIES RAISED WITH SYNTHETIC PEPTIDES, AS A SOURCE OF STANDARDS IN THE IMMUNOASSAYS, AND WILL ALSO SERVEAS THE ANTIGEN IN RAISING A FURTHER PANEL OF ANTIBODIES. SPECIFICITY OF THE ANTIBODIES WILL BE ASSESSED USING MEMBRANES DERIVED FROM DIFFERENT CELLS CONTAINING OR DEVOID OF THE BETA-2 RECEPTOR. FURTHER TESTS OF SPECIFICITY WILL ESTABLISH THE IMMUNOREACTIVE BAND ON WESTERN BLOTS AS BEING THE RECEPTOR BY CARRYING OUT IMMUNOPRECIPITATION OF THE PHOTOLABELED RECEPTOR. ONCE THE VALIDATION OF THE ANTIBODIES IS COMPLETE, A CLINICALLY USEFUL IMMUNOASSAY AS EIA WILL BE FORMULATED. THE ANTIBODIES WILL ALSO BE EVALUATED FOR THEIR UTILITY IN STRUCTURE/FUNCTION STUDIES OFTHE RECEPTOR. PRELIMINARY EVIDENCE IS GIVEN WHICH INDICATESTHAT ANTIBODIES TO SOME SYNTHETIC PEPTIDES MAY DETECT BOTH THE NATURAL AND RECOMBINANT RECEPTORS.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.